Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291055 · ClinicalTrials.gov registry record · Phase 1
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
A Phase 1 study, sponsored by Advaxis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT02291055: Clinical Trial Phase 1 study, sponsored by Advaxis.
NCT02291055 is a Phase 1 study that was terminated before completion, run by Advaxis. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02291055, a Phase 1 study, was terminated before completion, sponsored by Advaxis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of the cervix or metastatic human papillomaviruses (HPV)+ squamous cell carcinoma of the head and neck (SCCHN).
Interventions
- DRUG MEDI4736
- DRUG ADXS11-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2015-04 |
| Est. Completion | 2020-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02291055
The ClinicalTrials.gov registry entry for NCT02291055 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advaxis, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI4736 is the first listed.
NCT02291055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02291055 about?
NCT02291055 is a clinical study titled "A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer". This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of the cervix or metastatic human papillomaviruses (HPV)+ squamous cell car...
What is the current status of trial NCT02291055?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2015-04. Estimated completion is 2020-11-20.
What interventions are being tested in trial NCT02291055?
The interventions under investigation include: MEDI4736 (DRUG), ADXS11-001 (DRUG).
Who is sponsoring clinical trial NCT02291055?
This trial is sponsored by Advaxis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.